Phase 3 Dyslipidemia Clinical Trials
8 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–8 of 8 trials
Recruiting
Phase 3
Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
Type 2 DiabetesDyslipidemia
CMG Pharmaceutical Co. Ltd240 enrolled24 locationsNCT06772168
Recruiting
Phase 3
Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
Dyslipidemia Associated With Type II Diabetes Mellitus
EMS228 enrolled1 locationNCT04602754
Recruiting
Phase 3
Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
HypertensionDyslipidemia
JW Pharmaceutical162 enrolled1 locationNCT06643130
Recruiting
Phase 3
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
DyslipidemiasHypercholesterolemia
Hasten Biopharmaceutical Co., Ltd.210 enrolled18 locationsNCT06568471
Recruiting
Phase 3
Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia
Primary Hypercholesterolaemia and Mixed Dyslipidemia
Shanghai Junshi Bioscience Co., Ltd.582 enrolled1 locationNCT05621070
Recruiting
Phase 3
The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin
AtherosclerosisDyslipidemia
Wenzhou Medical University240 enrolled1 locationNCT02726555
Recruiting
Phase 2Phase 3
Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women
DyslipidemiasPostmenopausal SymptomsHypercholesterolemia+3 more
Dhurakij Pundit University10 enrolled1 locationNCT06220266
Not Yet Recruiting
Phase 3
A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145mg fenofibrate and simvastatin with 40mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone
Patients with mixed dyslipidemia with CHD or CHD risk equivalent or with multiple risk factor and a 10 year risk above or equal to 10% and with TG above 1.71mmol/l and LDL >2.58 or >3.36mmol/l according to risk after 6 weeks of treatment with 40mg simvastatin.
Fournier Laboratories Ireland400 enrolled1 locationACTRN12605000777695